The US Food and Drug Administration's report to Congress on lawful use of cannabidiol in food and dietary supplements left unanswered questions about issues including sustaining drug development with hemp- and cannabis-derived ingredients, says an attorney leading a CBD research collaborative.
Libby Baney, a partner at Faegre Drinker Biddle & Reath LLP in Washington, has suggestions for additional questions the FDA should answer about the safety of CBD before it considers...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?